NO20084502L - Tetrahydropyrrolopyrimidinedioner og deres anvendelse som humane neutrofil elastase inhibitorer - Google Patents

Tetrahydropyrrolopyrimidinedioner og deres anvendelse som humane neutrofil elastase inhibitorer

Info

Publication number
NO20084502L
NO20084502L NO20084502A NO20084502A NO20084502L NO 20084502 L NO20084502 L NO 20084502L NO 20084502 A NO20084502 A NO 20084502A NO 20084502 A NO20084502 A NO 20084502A NO 20084502 L NO20084502 L NO 20084502L
Authority
NO
Norway
Prior art keywords
tetrahydropyrrolopyrimidine
dione
neutrophil elastase
human neutrophil
elastase inhibitors
Prior art date
Application number
NO20084502A
Other languages
English (en)
Norwegian (no)
Inventor
Harry Finch
Nicholas Ray
Christine Edwards
Elizabeth O'connor
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0608844A external-priority patent/GB0608844D0/en
Priority claimed from GB0612544A external-priority patent/GB0612544D0/en
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of NO20084502L publication Critical patent/NO20084502L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20084502A 2006-05-04 2008-10-27 Tetrahydropyrrolopyrimidinedioner og deres anvendelse som humane neutrofil elastase inhibitorer NO20084502L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0608844A GB0608844D0 (en) 2006-05-04 2006-05-04 Enzyme inhibitors
GB0612544A GB0612544D0 (en) 2006-06-23 2006-06-23 Enzyme inhibitors
PCT/GB2007/001638 WO2007129060A1 (en) 2006-05-04 2007-05-03 Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors

Publications (1)

Publication Number Publication Date
NO20084502L true NO20084502L (no) 2008-11-26

Family

ID=38226415

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084502A NO20084502L (no) 2006-05-04 2008-10-27 Tetrahydropyrrolopyrimidinedioner og deres anvendelse som humane neutrofil elastase inhibitorer

Country Status (21)

Country Link
US (1) US8957082B2 (de)
EP (1) EP2024367B1 (de)
JP (1) JP4999920B2 (de)
AT (1) ATE480543T1 (de)
AU (1) AU2007246889B2 (de)
BR (1) BRPI0711169A2 (de)
CA (1) CA2657956C (de)
CY (1) CY1111437T1 (de)
DE (1) DE602007009095D1 (de)
DK (1) DK2024367T3 (de)
EA (1) EA018061B1 (de)
HK (1) HK1130794A1 (de)
IL (1) IL194843A (de)
MX (1) MX2008013996A (de)
NO (1) NO20084502L (de)
NZ (1) NZ572250A (de)
PL (1) PL2024367T3 (de)
PT (1) PT2024367E (de)
SI (1) SI2024367T1 (de)
WO (1) WO2007129060A1 (de)
ZA (1) ZA200809250B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
US8198288B2 (en) 2006-05-04 2012-06-12 Pulmagen Therapeutics (Inflammation) Limited Tetrahydropyrrolopyrimidinediones and their use in therapy
MX2008013996A (es) 2006-05-04 2009-01-14 Argenta Discovery Ltd Tetrahidropirrolopirimidindionas y su uso como inhibidores de elastasa de neutrofilo humano.
WO2009013444A1 (en) * 2007-07-25 2009-01-29 Argenta Discovery Limited Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
US20110003858A1 (en) * 2006-09-04 2011-01-06 Bergstroem Lena Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
PE20091565A1 (es) 2007-11-06 2009-11-06 Astrazeneca Ab Derivados de 2-pirazinona como inhibidores de la elastasa de los neutrofilos
GB0721866D0 (en) * 2007-11-07 2007-12-19 Argenta Discovery Ltd Pharmaceutical compounds having dual activities
WO2009060206A1 (en) * 2007-11-07 2009-05-14 Argenta Discovery Limited 3,4,6,7-tetrahydro-1h-pyrrolo[3,4-d]pyrimidine-2,5-diones and their therapeutic use
WO2009060158A1 (en) * 2007-11-07 2009-05-14 Argenta Discovery Limited 4- (4-cyanophenyl) -1- (3-trifluoromethylphenyl) -3,4, 6, 7-tetrahydro-1h-pyrrolo [3, 4- d] pyrimidine-2, 5-dione derivatives and their use as human neutrophil elastase inhibitors
PL2234985T3 (pl) 2007-12-20 2012-08-31 Bayer Ip Gmbh 4-(4-cyjano-2-tioarylo)-dihydropirymidynony i ich zastosowanie
DE102007061766A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung
DE102008052013A1 (de) 2008-10-17 2010-04-22 Bayer Schering Pharma Aktiengesellschaft 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung
DE102008022521A1 (de) 2008-05-07 2009-11-12 Bayer Schering Pharma Aktiengesellschaft 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung
GB0817429D0 (en) * 2008-09-23 2008-10-29 Argenta Discovery Ltd Enzyme inhibitors
DE102009004197A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung
US8455505B2 (en) 2009-01-30 2013-06-04 Chiesi Farmaceutici S.P.A. Pyrrolopyrimidinedione and its therapeutic use
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
CN102639505A (zh) 2009-10-02 2012-08-15 阿斯利康(瑞典)有限公司 用作嗜中性白细胞弹性蛋白酶抑制剂的吡啶-2-酮化合物
GB201004179D0 (en) * 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
GB201004178D0 (en) * 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
DE102010030187A1 (de) 2010-06-16 2011-12-22 Bayer Schering Pharma Aktiengesellschaft 4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung
AR087841A1 (es) * 2011-09-14 2014-04-23 Chiesi Farma Spa Derivados de tetrahidrotriazolopirimidina
US20140221335A1 (en) 2013-02-06 2014-08-07 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9115093B2 (en) 2013-03-04 2015-08-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
RU2016123379A (ru) 2013-12-16 2017-12-19 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Тетрагидротриазолопиримидиновые соединения в качестве ингибиторов нейтрофильной эластазы человека
USRE47493E1 (en) 2014-02-20 2019-07-09 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9487528B2 (en) 2014-06-09 2016-11-08 Chiesi Farmaceutici S.P.A. Compounds
US9440930B2 (en) 2014-07-31 2016-09-13 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9290457B2 (en) 2014-07-31 2016-03-22 Boehringer Ingelheim International Gmbh Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9657015B2 (en) * 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9475779B2 (en) * 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9458113B2 (en) 2014-07-31 2016-10-04 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
CA2980071A1 (en) 2015-03-18 2016-09-22 Bayer Pharma Aktiengesellschaft Method for preparation of (4s)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile
EP4031138A1 (de) 2019-09-17 2022-07-27 Mereo Biopharma 4 Limited Alvelestat zur verwendung bei der behandelung von transplantatabstossung, bronchiolitis-obliterans-syndrom und transplantat-gegen-wirtszelle
AU2021256835A1 (en) 2020-04-16 2022-10-13 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
WO2023067103A1 (en) 2021-10-20 2023-04-27 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9626643D0 (en) 1996-12-21 1997-02-12 Astra Pharma Prod Compounds
PE107899A1 (es) 1997-09-09 1999-11-17 Glaxo Group Ltd Derivados de pirrolopirrolona como inhibidores de elastasa leucocitaria
US6630476B2 (en) 2000-07-07 2003-10-07 Bristol-Myers Squibb Pharma Company Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists
EP1539710B1 (de) * 2002-09-10 2010-10-27 Bayer Schering Pharma Aktiengesellschaft Heterocyclische derivate
BR0314186A (pt) 2002-09-10 2005-08-09 Bayer Healthcare Ag Derivados de pirimidinona como agentes terapêuticos contra processos inflamatórios, isquêmicos e remodeladores, agudos e crÈnicos
GB0502258D0 (en) * 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
GB0520743D0 (en) * 2005-10-12 2005-11-23 Argenta Discovery Ltd Compounds and their use
MX2008013996A (es) 2006-05-04 2009-01-14 Argenta Discovery Ltd Tetrahidropirrolopirimidindionas y su uso como inhibidores de elastasa de neutrofilo humano.

Also Published As

Publication number Publication date
EA200870391A1 (ru) 2009-06-30
AU2007246889B2 (en) 2011-03-10
DE602007009095D1 (de) 2010-10-21
MX2008013996A (es) 2009-01-14
CA2657956A1 (en) 2007-11-15
ATE480543T1 (de) 2010-09-15
IL194843A0 (en) 2009-08-03
CA2657956C (en) 2015-01-06
IL194843A (en) 2014-04-30
WO2007129060A1 (en) 2007-11-15
EP2024367A1 (de) 2009-02-18
US20120202826A1 (en) 2012-08-09
ZA200809250B (en) 2010-02-24
PT2024367E (pt) 2010-12-03
SI2024367T1 (sl) 2011-04-29
NZ572250A (en) 2011-10-28
DK2024367T3 (da) 2011-01-03
HK1130794A1 (en) 2010-01-08
AU2007246889A1 (en) 2007-11-15
EP2024367B1 (de) 2010-09-08
PL2024367T3 (pl) 2011-05-31
CY1111437T1 (el) 2015-08-05
JP4999920B2 (ja) 2012-08-15
US8957082B2 (en) 2015-02-17
BRPI0711169A2 (pt) 2011-08-23
JP2009535389A (ja) 2009-10-01
EA018061B1 (ru) 2013-05-30

Similar Documents

Publication Publication Date Title
NO20084502L (no) Tetrahydropyrrolopyrimidinedioner og deres anvendelse som humane neutrofil elastase inhibitorer
CY2023004I1 (el) Συνθεσεις irna τρανσθυρετινης (ttr) και μεθοδοι χρησεως αυτων για τη θεραπευτικη αγωγη ή προληψη σχετιζομενων me ttr ασθενειων
DE602007005120D1 (de) 2-pyridonderivate zur behandlung von krankheiten oder leiden, bei denen eine inhibierung der aktivität der neutrophilen elastase von nutzen ist
EA200802213A1 (ru) Способы лечения заболеваний крови
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
TR201907874T4 (tr) Düşük sülfat fukanlar kullanarak fibröz yapışmaları ya da inflamatuar hastalıkları inhibe etmeye yönelik farmasötik kompozisyonlar ve yöntemler.
ATE416177T1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
EA200901442A1 (ru) Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах
NO20084749L (no) Organiske forbindelser og deres anvendelser
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
HK1135103A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
ECSP077223A (es) Indazoles utiles en el tratamiento de enfermedades cardiovasculares
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
EA201170521A1 (ru) Новые соединения
EA200870019A1 (ru) Лактамовые соединения и способы их применения
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
NO20092639L (no) 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav
ATE456955T1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
NO20076405L (no) Anvendelse av 24-nor-UDCA
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
ATE518853T1 (de) Verbindungen zur behandlung entzündlicher erkrankungen
CY1112128T1 (el) Χρηση il-18bp ισομορφων για την αντιμετωπιση και/ή προληψη νευρολογικων φλεγμονωδων νοσων
CY1114807T1 (el) Ενωσεις 2,4-πυριμιδινοδιαμινης για τη θεραπευτικη αντιμετωπιση ή την προληψη αυτοανοσων νοσων

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: CHIESI FARMACEUTICI SPA, IT